Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights

dnrt8765

• First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis • First Subject Dosed in Phase 2a Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19 • Clinical Trial of ATI-1777, an Investigational “Soft” Topical JAK 1/3 Inhibitor, to Proceed in Patients with Moderate to Severe Atopic Dermatitis

WAYNE, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second

Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update

dnrt8765

— EXPAREL average daily sales return to year-over-year growth in month of June 2020 —
— Conference call today at 8:30 a.m. ET —

PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today reported financial results for the second quarter of 2020.

“We are very pleased to report that since the peak of the impact from COVID-19 in April, we’ve seen a steady and continued increase in EXPAREL sales. This is a testimony to the resolve of our physician partners who are dedicated to ensuring that

Savara Reports Second Quarter 2020 Financial Results and Provides Business Update

dnrt8765

AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.

With a final design for IMPALA 2, we are working diligently on study preparations and expect it to start in the first quarter of next year,” said Rob Neville, Chief Executive Officer, Savara. “Building on the learnings from the first IMPALA study, and following constructive discussions with the regulatory agencies, we are confident in the study design and believe IMPALA 2 will effectively measure the potential efficacy

Tucows Reports Financial Results for Second Quarter 2020

dnrt8765

TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) — Tucows Inc. (NASDAQ:TCX, TSX:TC), a provider of network access, domain names and other Internet services, today reported its financial results for the second quarter ended June 30, 2020. All figures are in U.S. dollars.

COVID-19:  Tucows shareholders and prospective investors are encouraged to read Tucows’ public statement regarding COVID-19, which is available here: https://bit.ly/2LavpOc.

Summary Financial Results
(In Thousands of US Dollars, Except Per Share Data)

  3 Months ended June 30 6 Months ended June 30
2020
(Un-
audited)
2019
(Un-
audited)
% Change 2020
(Un-
audited)
2019
(Un-
audited)
% Change